-
Educating the public about biosimilars
Dr. Abimbola Farinde PharmaceuticalIn recent years, knowledge of the existence of biosimilars has grown. A biosimilar is a biologic medicine that is shown to be similar to an approved innovative biological product or drug. Unlike generic drugs, in which the active ingredients are identical, biosimilars do have key differences from the reference product.
-
Why should pharmacies notify physicians about rejections?
Jason Poquette PharmaceuticalWill Rogers apparently once quipped, "I don't make jokes. I just watch the government and report the facts." Rogers would have a field day with some of the "facts" that are coming out lately.
-
Ibuprofen: Exceeding the daily dosing limits
Dorothy L. Tengler Medical & Allied HealthcareNonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used drugs worldwide to treat mild-to-moderate pain and inflammation. The widespread availability of over-the-counter NSAIDs such as ibuprofen, aspirin and sodium naproxen, for example, has allowed tens of millions of individuals to minimize the pain, swelling and inflammation linked with mild moderate athletic injuries.
-
States introducing legislation to import Canadian drugs
Michelle R. Matisons PharmaceuticalThe rising cost of prescription drugs is not a new story. But as continuing efforts to lower prices have had little effect, states are starting to take matters into their own hands.
-
How will the new HIV drug approval affect patients?
Dr. Abimbola Farinde PharmaceuticalSince the formal recognition of the human immunodeficiency virus (HIV) in 1981 in the United States, there have been ongoing research efforts to both better understand the cause of HIV and to develop effective antiretroviral drugs to target the virus. The introduction of a new antiretroviral agent into the therapeutic landscape of the HIV drug market has brought both optimism toward meeting this goal and conflict among two competing pharmaceutical companies.
-
Scope of nanotechnology widens in 2018
Bill Becken EngineeringThere's miniaturization, and then there's nanotechnology. Global markets are growing and multiplying for both. But it's the point of nanotech to effect desired technical solutions and outcomes with ever-smaller — much, much smaller — building blocks of materials.
-
The pharmacist as motivator
Jason Poquette Pharmaceutical"Imagine your life is perfect in every respect; what would it look like?" This question, posed by motivational speaker and author Brian Tracy, is at the heart of much that he writes about. See where you want to be. Imagine a better life. Then, begin to work backward toward achieving it.
-
Hope on the horizon for Puerto Rico drug shortages
Dr. Abimbola Farinde PharmaceuticalIn the wake of the two hurricanes that devastated Puerto Rico's way of life, the United States has experienced shortages of certain drugs. The magnitude of this impact has been felt by many hospitals across the United States that depend on a number of Baxter products, which are made in Puerto Rico.
-
Healthcare megadeals led the way in 2017 — and there’s more to…
Scott E. Rupp PharmaceuticalTurns out the first year of the Donald Trump administration was an active year for U.S. health services deals, with deal volume decreasing slightly from 2016, but deal value increasing significantly. Even without 2017's largest transaction — CVS buying Aetna for $69 billion, which accounted for almost 44 percent of total deal value — the total would have been 40 percent greater than 2016 levels. Those are epic numbers.
-
In West Virginia, overdose deaths rise as opioid prescriptions drop
Jason Poquette PharmaceuticalRecently released information from the West Virginia Board of Pharmacy (BOP) about their state opioid abuse problem confirms what many of us have been saying for years: Addiction and overdose deaths are not, primarily, a prescribing and dispensing problem.
All Pharmaceutical Articles